An In Vivo Microdialysis Study of FLZ Penetration through the Blood-Brain Barrier in Normal and 6-Hydroxydopamine Induced Parkinson’s Disease Model Rats
Figure 3
Blood dialysate FLZ profiles for the different treatment groups ( per group). (a) FLZ concentrations measured in blood dialysates at different time points in the FLZ only-N and FLZ only-PD groups. A significant difference was observed at the second time point only (30 min). (b) FLZ concentrations measured at different time points in blood dialysates from the FLZ only-N and FLZ + ZOSUQ-N groups. FLZ levels decreased significantly between the sixth and fourteenth samples in the FLZ + ZOSUQ-N group relative to those in the FLZ only-N group. (c) FLZ concentrations measured at different time points in blood dialysates from the FLZ only-PD and FLZ + ZOSUQ-PD groups. There was a significant reduction in FLZ levels in the FLZ + ZOSUQ-PD compared with the FLZ only-PD group (the first to the tenth sample). (d) FLZ concentrations in blood dialysates measured at different time points in the FLZ + ZOSUQ-N and FLZ + ZOSUQ-PD groups. There was no statistical difference in FLZ levels between the two groups. ; . Data are expressed as the mean ± SD. Note: FLZ dialysate samples from the FLZ only-N and FLZ only-PD groups were collected for 3.5 hours (brain dialysate concentrations after this period were below the limit of quantification).
